News | July 05, 2024
GSK and CureVac restructure collaboration into new licensing agreement
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
